Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 491

1.

New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).

Pouga L, Mercedes Santoro M, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S.

Chem Biol Drug Des. 2018 Aug 13. doi: 10.1111/cbdd.13378. [Epub ahead of print]

PMID:
30103267
2.

Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy.

Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; Icona Foundation Study Group.

BMC Public Health. 2018 Jul 13;18(1):870. doi: 10.1186/s12889-018-5804-z.

3.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets.

Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V.

Viruses. 2018 Jul 9;10(7). pii: E363. doi: 10.3390/v10070363.

4.

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C).

Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y.

5.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

6.

First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group.

HIV Med. 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print]

PMID:
29846042
7.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print]

PMID:
29808463
8.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group.

BMC Med. 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2.

9.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, Lazzarin A, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M.

New Microbiol. 2018 Apr;41(2):112-117.

10.

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.

Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G.

Infection. 2018 May 26. doi: 10.1007/s15010-018-1158-9. [Epub ahead of print]

PMID:
29804205
11.

The degree of HIV-1 amino acid variability is strictly related to different disease progression rates.

Scutari R, Faieta M, D'Arrigo R, Fabeni L, Mussini C, Cossarizza A, Casoli C, Perno CF, Svicher V, Alteri C, Aquaro S.

Virus Genes. 2018 Aug;54(4):493-501. doi: 10.1007/s11262-018-1571-2. Epub 2018 May 17.

PMID:
29777446
12.

Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.

Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group.

BMC Infect Dis. 2018 May 16;18(1):223. doi: 10.1186/s12879-018-3125-6.

13.

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, Santoro MM.

J Clin Virol. 2018 Jul;104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3.

PMID:
29738896
14.

Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39].

Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F.

Drug Resist Updat. 2018 Apr 18. pii: S1368-7646(18)30024-4. doi: 10.1016/j.drup.2018.04.001. [Epub ahead of print] No abstract available.

PMID:
29680499
15.

High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance.

Malagnino V, Salpini R, Maffongelli G, Battisti A, Fabeni L, Piermatteo L, Colagrossi L, Fini V, Ricciardi A, Sarrecchia C, Perno CF, Andreoni M, Svicher V, Sarmati L.

PLoS One. 2018 Mar 29;13(3):e0195045. doi: 10.1371/journal.pone.0195045. eCollection 2018.

16.

Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children.

Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, Takou D, Temgoua ES, Tangimpundu C, Torimiro JN, Koki PN, Fokunang CN, Cappelli G, Ndjolo A, Colizzi V, Ceccherini-Silberstein F, Perno CF, Santoro MM.

Medicine (Baltimore). 2018 Mar;97(13):e0176. doi: 10.1097/MD.0000000000010176.

17.

Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F; AMCLI-GLaIT working group.

Biol Blood Marrow Transplant. 2018 Mar 12. pii: S1083-8791(18)30118-6. doi: 10.1016/j.bbmt.2018.03.005. [Epub ahead of print]

PMID:
29545186
18.

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.

Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F.

Drug Resist Updat. 2018 Mar;37:17-39. doi: 10.1016/j.drup.2018.01.004. Epub 2018 Feb 21. Review. Erratum in: Drug Resist Updat. 2018 Apr 18;:.

PMID:
29525636
19.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

20.

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes D.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):125-135. doi: 10.1097/QAI.0000000000001660.

Supplemental Content

Loading ...
Support Center